Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (ADC) technologies. The transaction, announced this week, adds to a growing list of multibillion-dollar ADC and T-cell engager (TCE) deals, highlighting continued strategic investment in differentiated antibody platforms.
VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology's most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The Novartis acquisition reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies. Novartis gains access to Myricx Bio's novel N-myristoyltransferase inhibitor (NMTi) payload platform and two lead ADC programs.
The Novartis transaction follows a series of major antibody therapeutics deals, including Jazz Pharmaceuticals' collaboration with AbCellera, Gilead Sciences' acquisition of Tubulis and multiple multibillion-dollar ADC licensing agreements. VERAXA is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented BiTAC platform, positioning the company within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations and acquisition activity.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
The latest news and updates relating to VRXA are available in the company's newsroom at http://ibn.fm/VRXA. This acquisition activity signals that pharmaceutical companies are willing to pay significant premiums for differentiated ADC platforms, which bodes well for VERAXA as it continues to develop its own pipeline.
